Stem Cell gets patents in U.S. and Japan

Stem Cell Therapeutics (TSX-V:SSS) has received notification of the issuance of two new patents in the U.S. and Japan. The U.S. patent relates to the use of the pregnancy hormone, human chorionic gonadotropin (hCG), to treat patients presenting with damaged or diseased heart cells. The Japanese patent relates to the use of granulocyte colony stimulating [...]

biOasis posts positive results of Herceptin delivery to brain

biOasis Technologies (TSX-V:BTI) has announced positive results from its BT2111 program, showing that the company’s Transcend vector delivers trastuzumab , or Herceptin, across the blood-brain barrier and into brain tissue. Trastuzumab is a humanized monoclonal antibody used to treat HER2-positive breast cancer. However, it is not able to treat breast cancer metastases to the brain [...]

Theralase starts testing PDCs against cancer

Theralase Technologies (TSX-V: TLT) has started the preclinical trial phase of its cancer research project, evaluating its photodynamic compounds (PDCs) in a small animal in-vivo model. “Successful completion of this milestone will lay the groundwork for exploring the use of these PDCs in the destruction of cancers in larger animals including, horses, cats, dogs and [...]

DiaMedica in research pact with Sanford Project

DiaMedica (TSX-V:DMA) has begun a research collaboration with the Sanford Project, a world leader in Type 1 diabetes research. Dr. Alexi Savinov, an associate scientist at Sanford, will be performing a definitive study in the non-obese diabetic mouse model, using DiaMedica’s DM-199 to measure the dual actions of the drug candidate, including the protection/regeneration of [...]

Immunovaccine has positive RA preclinical results

Immunovaccine (TSX-V:IMV) has released positive results of a preclinical study testing the efficacy of combining CEL-2000, CEL-SCI Corp.’s (AMEX: CVM) rheumatoid arthritis vaccine antigen, and DepoVax, Immunovaccine’s delivery platform. The study results showed the vaccine combination “considerably lessened the symptoms and slowed the progression of RA” in the animal model with a single dose.  The [...]

Theralase heals at the speed of light

In the early 1990s, Roger Dumoulin-White’s father, a jeweller in Tillsonburg, ON, showed his son a prototype laser system that healed tissue. “I was pretty sceptical,” Mr. Dumoulin-White remembers.  “It was something my father came across while traveling in Europe.  He also gave me an anecdotal study translated from Flemish that showed using 905 nanometre [...]

Miraculins develops new assay in preeclampsia program

Miraculins (TSX-V:MOM) has developed an ultrasensitive assay for the detection of soluble endoglin, optimized for serum and urine, in an ELISA format as part of its preeclampsia program.  Endoglin is the lead biomarker in its preeclampsia portfolio. “Our initial focus will be to offer this assay to investigators as a research-use-only kit to support preeclampsia [...]

Sernova to raise $1.2 million in private placement

Sernova (TSX-V:SVA) is offering up to eight million units at a price of 15 cents each to raise up to $1.2 million in a non-brokered private placement and has completed the first closing under the offering, raising $405,250 through the sale of 2,701,666 units. Each unit consists of one common share and one-half of a [...]

IntelGenx to license anti-migraine film product

IntelGenx (TSX-V:IGX) has signed a binding term-sheet with closely held RedHill Biopharma of Israel to co-develop and license IntelGenx’s rapidly dissolving anti-migraine oral film product based on its VersaFilm technology. “We are excited to have concluded our first, of what we believe to be many future, thin film partnerships,” CEO Dr. Horst Zerbe said in [...]

Miraculins amends private placement offering

Miraculins (TSX-V:MOM) has raised the number of units in a previously announced private placement to 10 million from 7.5 million, with the units priced at five cents each instead of seven cents, for gross proceeds of $500,000. Each unit will consist of one common share of the company and one warrant.  Each warrant can be [...]

Next Page »